Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome
Irritable Bowel Syndrome
About this trial
This is an interventional supportive care trial for Irritable Bowel Syndrome
Eligibility Criteria
Inclusion Criteria: Provision of Free and Informed Consent in writing, signed and dated; Age according to the indicated population; Patients diagnosed with IBS by a specialist. Exclusion Criteria: Individuals with a history of daily consumption of probiotics, fermented milk and / or yogurt; subjects known to have demonstrated a prior reaction, including anaphylaxis, to any substance in the composition of the study product; Individuals who have unbalanced blood pressure; hx of heart disease, including valvulopathies or any implantable device; individuals on immunosuppressive therapy or any health condition causing immunosuppression; individuals with active, uncontrolled bowel disease such as Crohn's disease or ulcerative colitis; Women who are pregnant at the time of enrollment or who plan to become pregnant during the study; Individuals with concomitant participation in another clinical trial; History of autoimmune disease.
Sites / Locations
- Universidade Do Extremo Sul CatarinenseRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Probiotic blend group
Placebo group
Volunteers supplemented with the probiotic product (n=57) (Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 10e10 CFU/day).
Placebo Group (n=57): Volunteers supplemented with placebo (maltodextrin)